DMAC vs PPL · $157.4M cap vs P/E 22, rev $8.46B
DiaMedica Therapeutics Inc (DMAC) versus PPL Corporation (PPL) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
PPL Corporation (PPL) is a utilities - regulated electric company listed on NYSE.
DMAC does not have a complete income-statement cache yet.
Latest reported PPL revenue for 2024-12-31 was $8.46B. Net income was $888.0M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. PPL currently screens at market cap $26.58B and trailing P/E 21.7.
DMAC currently screens at market cap $157.4M. PPL currently screens at market cap $26.58B and trailing P/E 21.7.
Not investment advice. Open the DMAC and PPL stock pages for the full models.
Not investment advice.